Side effects of Relvar include:
Pneumonia, or other upper respiratory tract infections like bronchitis or influenza
Candidiasis of mouth and throat
Nervous system disorders
Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate. For example, in patients not adequately controlled with inhaled corticosteroids and using ‘as needed’ inhaled short acting beta2-agonists. Dosing for asthma 92/22 mcg, 184/22mcg.
Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy. Dosing for COPD 92/22 mcg only